OSE OSE Immunotherapeutics SA

OSE Immunotherapeutics annonce l’accord de délivrance d’un brevet en Europe protégeant FR104, immunothérapie first-in-class antagoniste du CD28

OSE Immunotherapeutics annonce l’accord de délivrance d’un brevet en Europe protégeant FR104, immunothérapie first-in-class antagoniste du CD28
FR
12/10/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on OSE Immunotherapeutics SA

Jamila El Bougrini ... (+2)
  • Jamila El Bougrini
  • Thibaut Voglimacci-Stephanopoli

ResearchPool Subscriptions

Get the most out of your insights

Get in touch